You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

16 Results
Guidelines and Advice
Status: Current
ID: 4-17
Version: 2
Jan 2018
Guidelines and Advice
Status: Current
ID: 8-6
Version: 2
Aug 2018
Guidelines and Advice
Status: In-Review
ID: 12-12-2
Version: 2
Nov 2018
Guidelines and Advice
Status: Current
ID: 8-7
Version: 2
Mar 2023
Drug
Other Name(s): Nexavar®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2023
Drug
Other Name(s): Sutent®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Advanced hepatocellular carcinoma, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
SORAfenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2023
Guidelines and Advice
Status: In-Review
ID: 6-13
Mar 2018
Guidelines and Advice
Status: Current
Version: 1
Jun 2018
Guidelines and Advice
Status: Current
ID: N/A
Version: 1
Nov 2018
Statistical Reports
Jan 2018
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Sacituzumab Govitecan - Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
sacituzumab govitecan
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2023

Pages